LT2497500T - Spinalinės raumenų atrofijos genų terapija - Google Patents

Spinalinės raumenų atrofijos genų terapija

Info

Publication number
LT2497500T
LT2497500T LTEP12157957.7T LT12157957T LT2497500T LT 2497500 T LT2497500 T LT 2497500T LT 12157957 T LT12157957 T LT 12157957T LT 2497500 T LT2497500 T LT 2497500T
Authority
LT
Lithuania
Prior art keywords
gene therapy
muscular atrophy
spinal muscular
spinal
atrophy
Prior art date
Application number
LTEP12157957.7T
Other languages
English (en)
Inventor
Catherine O`Riordan
Samuel Wadsworth
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of LT2497500T publication Critical patent/LT2497500T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6027—Vectors comprising as targeting moiety peptide derived from defined protein from viruses ssDNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP12157957.7T 2006-10-03 2007-10-03 Spinalinės raumenų atrofijos genų terapija LT2497500T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82797706P 2006-10-03 2006-10-03

Publications (1)

Publication Number Publication Date
LT2497500T true LT2497500T (lt) 2016-12-27

Family

ID=39269037

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP12157957.7T LT2497500T (lt) 2006-10-03 2007-10-03 Spinalinės raumenų atrofijos genų terapija
LT16184966T LT3146982T (lt) 2006-10-03 2007-10-03 Amiotrofinės lateralinės sklerozės ir kitų nugaros smegenų sutrikimų genų terapija

Family Applications After (1)

Application Number Title Priority Date Filing Date
LT16184966T LT3146982T (lt) 2006-10-03 2007-10-03 Amiotrofinės lateralinės sklerozės ir kitų nugaros smegenų sutrikimų genų terapija

Country Status (13)

Country Link
US (2) US9890394B2 (lt)
EP (4) EP3632472A1 (lt)
CN (3) CN101528922A (lt)
AR (1) AR063113A1 (lt)
CY (1) CY1118477T1 (lt)
DK (2) DK2066791T3 (lt)
ES (3) ES2757723T3 (lt)
HU (2) HUE031182T2 (lt)
LT (2) LT2497500T (lt)
PL (2) PL2066791T3 (lt)
PT (3) PT2066791E (lt)
SI (3) SI2497500T1 (lt)
WO (1) WO2008042420A2 (lt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2066791T3 (da) 2006-10-03 2012-10-15 Genzyme Corp Genterapi for amyotrofisk lateralsklerose og andre rygmarvssygdomme
WO2009090933A1 (ja) * 2008-01-16 2009-07-23 Japan Science And Technology Agency 低酸素状態にある細胞で増殖するウイルスまたは遺伝子を発現するウイルスベクター
SG10202109219SA (en) 2009-05-02 2021-10-28 Genzyme Corp Gene therapy for neurodegenerative disorders
US9770471B2 (en) 2011-08-17 2017-09-26 President And Fellows Of Harvard College Conversion of somatic cells into functional spinal motor neurons, and methods and uses thereof
RU2020108189A (ru) 2014-11-14 2020-03-11 Вояджер Терапьютикс, Инк. Композиции и способы лечения бокового амиотрофического склероза (als)
MX2017006217A (es) 2014-11-14 2018-05-02 Voyager Therapeutics Inc Polinucleotidos moduladores.
CN107427666B (zh) * 2015-01-30 2022-11-04 加利福尼亚大学校董 脊髓软膜下基因递送系统
CL2015003024A1 (es) 2015-10-09 2016-05-13 Univ Chile Método de tratamiento genético utilizando el virus aav-xbp1s/gfp, y su uso en la prevención y tratamiento de la esclerosis lateral amiotrofica.
CN108884022B (zh) 2016-03-28 2022-01-28 加利福尼亚大学董事会 用于治疗神经元的过度兴奋的方法和组合物
AU2017267665C1 (en) 2016-05-18 2023-10-05 Voyager Therapeutics, Inc. Modulatory polynucleotides
SG10202105090WA (en) * 2016-11-17 2021-06-29 Nationwide Childrens Hospital Inc Intrathecal delivery of recombinant adeno-associated virus encoding methyl-cpg binding protein 2
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
CA3061652A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
CA3109159A1 (en) * 2017-08-16 2019-02-21 Lgv1 S.R.L. Vtft isoform of a bpifb4 protein for use in neuronal diseases and injuries
AU2018327253B2 (en) 2017-09-08 2024-05-16 The Regents Of The University Of California Method and composition for treating neuropathic pain
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
CN111479924B (zh) 2017-10-16 2024-06-14 沃雅戈治疗公司 肌萎缩性侧索硬化症(als)的治疗
KR102860879B1 (ko) 2019-01-10 2025-09-17 더 리전츠 오브 더 유니버시티 오브 캘리포니아 연막하 전달 시스템 및 사용 방법
USD963164S1 (en) 2020-01-09 2022-09-06 The Regents Of The University Of California Surgical needle
EP4370679A4 (en) * 2021-07-16 2025-11-12 Harvard College ACTIVATORS DIRECTING THE EXPRESSION OF MOTOR NEURONS

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8303626D0 (sv) 1983-06-23 1983-06-23 Kabigen Ab A recombinant plasmid a transformant microorganism, a polydoxyrebonucleotide segment, a process for producing a biologically active protein, and the protein thus produced
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
ES2249761T3 (es) 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
SK283703B6 (sk) 1993-10-25 2003-12-02 Canji, Inc. Rekombinantný adenovírusový vektor a jeho použitie
DE69433592T2 (de) 1993-11-09 2005-02-10 Targeted Genetics Corp., Seattle Die erzielung hoher titer des rekombinanten aav-vektors
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
WO1995028493A1 (en) 1994-04-13 1995-10-26 The Rockefeller University Aav-mediated delivery of dna to cells of the nervous system
US5882914A (en) 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
WO1997039789A1 (en) 1996-04-22 1997-10-30 Medtronic, Inc. Two-stage angled venous cannula
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
US20030104973A1 (en) * 1997-08-21 2003-06-05 Quark Biotech, Inc. Hypoxia-regulated genes
IL136454A0 (en) * 1997-12-04 2001-06-14 Genzyme Corp Compositions and methods for inducing gene expression
US6124131A (en) 1998-08-25 2000-09-26 The Johns Hopkins University School Of Medicine Mutant hypoxia inducible factor-1 HIF-1
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
DE60115070T2 (de) 2000-09-18 2006-07-27 Genzyme Corp., Cambridge Expressionsvektoren mit hybriden ubiquitin-promotoren
US6838430B2 (en) * 2001-09-28 2005-01-04 The Regents Of The University Of California Use of HIF-1a variants to accelerate wound healing
EP1478236B1 (en) * 2001-12-21 2009-02-11 The Salk Institute For Biological Studies Targeted retrograde gene delivery to motor neurons
US7193053B2 (en) * 2003-04-25 2007-03-20 United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hypoxia-inducible factor 1alpha variants and methods of use
GB2414934A (en) * 2004-06-11 2005-12-14 Gill Steven Streatfield Treatment of Parkinson's disease with GDNF
DK2066791T3 (da) 2006-10-03 2012-10-15 Genzyme Corp Genterapi for amyotrofisk lateralsklerose og andre rygmarvssygdomme
LT2773354T (lt) 2011-11-01 2019-08-12 Resverlogix Corp. Geriamosios greitai atsipalaiduojančios pakeistų chinozolinų vaisto formos

Also Published As

Publication number Publication date
PT3146982T (pt) 2019-10-31
ES2391789T3 (es) 2012-11-29
ES2757723T3 (es) 2020-04-30
PL2497500T3 (pl) 2017-07-31
PL2066791T3 (pl) 2013-02-28
PT2497500T (pt) 2016-11-23
DK2497500T3 (da) 2017-01-02
EP2497500A1 (en) 2012-09-12
CN101528922A (zh) 2009-09-09
EP3146982A1 (en) 2017-03-29
SI3146982T1 (sl) 2019-11-29
US20180230490A1 (en) 2018-08-16
EP2066791A2 (en) 2009-06-10
AR063113A1 (es) 2008-12-30
US9890394B2 (en) 2018-02-13
EP2497500B1 (en) 2016-09-28
EP3632472A1 (en) 2020-04-08
PT2066791E (pt) 2012-12-05
EP3146982B1 (en) 2019-08-21
US10920245B2 (en) 2021-02-16
CN108853517A (zh) 2018-11-23
ES2607060T3 (es) 2017-03-29
CY1118477T1 (el) 2017-07-12
CN105770910A (zh) 2016-07-20
EP2066791A4 (en) 2010-11-03
US20090286857A1 (en) 2009-11-19
HUE046709T2 (hu) 2020-03-30
LT3146982T (lt) 2019-11-11
SI2497500T1 (sl) 2017-01-31
SI2066791T1 (sl) 2013-01-31
WO2008042420A2 (en) 2008-04-10
DK2066791T3 (da) 2012-10-15
HUE031182T2 (en) 2017-06-28
EP2066791B1 (en) 2012-09-12
WO2008042420A3 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
PL2497500T3 (pl) Terapia genowa rdzeniowego zaniku mięśni
GB0620400D0 (en) Spinal implant
EP2094350A4 (en) GROUPED ELECTRODES FOR BACKMARK STIMULATION
ZA200807936B (en) Compounds for the treatment of spinal muscular atrophy and other uses
IL197316A0 (en) Buprenophine-wafer for drug substitution therapy
EP2078536A4 (en) MEDICAL DEVICE
IL196559A0 (en) Combination therapy
GB0602178D0 (en) Therapeutic treatment
IL196702A0 (en) Trauma therapy
IL196556A0 (en) Combination therapy
EP2180855A4 (en) SPINAL CORRECTION DEVICE
EP2054061A4 (en) COMBINATION THERAPY
GB0618930D0 (en) Medical implant
GB0624200D0 (en) Wheelchairs
EP2099389A4 (en) IMPLANTABLE INTERVERTEBRAL DISC
ZA200902203B (en) Combination therapy
GB0608655D0 (en) Therapeutic Treatment
EP2022454A4 (en) WHEELCHAIR
GB0602768D0 (en) Treatment of muscular dystrophy
GB0610909D0 (en) Therapeutic treatment
GB0617299D0 (en) Compounds for imaging and therapy
GB0607153D0 (en) Therapeutic Method
GB0603773D0 (en) Surgical electrode
GB0602767D0 (en) Treatment of muscular dystrophy
IL255035A0 (en) Gene therapy for spinal cord disorders